A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Tango Therapeutics, Inc.
Verastem, Inc.
GlaxoSmithKline
Novartis
Novartis
Servier
Varian, a Siemens Healthineers Company
Sensome
Creo Medical Limited
Novartis
Amgen
Eli Lilly and Company
Pfizer
Hoffmann-La Roche
Eli Lilly and Company
Pfizer
Pfizer
Integro Theranostics
Pfizer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Merck Sharp & Dohme LLC
Pheon Therapeutics
Eli Lilly and Company
Teclison Ltd.
AstraZeneca
AstraZeneca
Bristol-Myers Squibb
ArriVent BioPharma, Inc.
Achieve Life Sciences
Iovance Biotherapeutics, Inc.
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
Boehringer Ingelheim
Zymeworks BC Inc.
Travera Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Hoffmann-La Roche
Tango Therapeutics, Inc.
Everest Detection, Inc.
Bristol-Myers Squibb
IDEAYA Biosciences
Merck Sharp & Dohme LLC
Endowave Ltd.
Pfizer
Revolution Medicines, Inc.
Genmab
AstraZeneca